These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 10866684)

  • 1. Disruption of Myc-tubulin interaction by hyperphosphorylation of c-Myc during mitosis or by constitutive hyperphosphorylation of mutant c-Myc in Burkitt's lymphoma.
    Niklinski J; Claassen G; Meyers C; Gregory MA; Allegra CJ; Kaye FJ; Hann SR; Zajac-Kaye M
    Mol Cell Biol; 2000 Jul; 20(14):5276-84. PubMed ID: 10866684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt's lymphoma cell lines.
    Albert T; Urlbauer B; Kohlhuber F; Hammersen B; Eick D
    Oncogene; 1994 Mar; 9(3):759-63. PubMed ID: 8108117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells.
    Gregory MA; Hann SR
    Mol Cell Biol; 2000 Apr; 20(7):2423-35. PubMed ID: 10713166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional analysis of Burkitt's lymphoma mutant c-Myc proteins.
    Smith-Sørensen B; Hijmans EM; Beijersbergen RL; Bernards R
    J Biol Chem; 1996 Mar; 271(10):5513-8. PubMed ID: 8621409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain.
    Hoang AT; Lutterbach B; Lewis BC; Yano T; Chou TY; Barrett JF; Raffeld M; Hann SR; Dang CV
    Mol Cell Biol; 1995 Aug; 15(8):4031-42. PubMed ID: 7623799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burkitt's lymphoma-associated c-Myc mutations converge on a dramatically altered target gene response and implicate Nol5a/Nop56 in oncogenesis.
    Cowling VH; Turner SA; Cole MD
    Oncogene; 2014 Jul; 33(27):3519-27. PubMed ID: 24013231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging molecular networks in Burkitt's lymphoma.
    Mangani D; Roberti A; Rizzolio F; Giordano A
    J Cell Biochem; 2013 Jan; 114(1):35-8. PubMed ID: 22903691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas.
    Bhatia K; Huppi K; Spangler G; Siwarski D; Iyer R; Magrath I
    Nat Genet; 1993 Sep; 5(1):56-61. PubMed ID: 8220424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression.
    Suk FM; Lin SY; Lin RJ; Hsine YH; Liao YJ; Fang SU; Liang YC
    Oncotarget; 2015 Sep; 6(28):25988-6001. PubMed ID: 26317903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line.
    Bemark M; Neuberger MS
    Oncogene; 2000 Jul; 19(30):3404-10. PubMed ID: 10918597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuberous sclerosis complex is required for tumor maintenance in MYC-driven Burkitt's lymphoma.
    Hartleben G; Müller C; Krämer A; Schimmel H; Zidek LM; Dornblut C; Winkler R; Eichwald S; Kortman G; Kosan C; Kluiver J; Petersen I; van den Berg A; Wang ZQ; Calkhoven CF
    EMBO J; 2018 Nov; 37(21):. PubMed ID: 30237309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retinoic acid induces persistent, RARalpha-mediated anti-proliferative responses in Epstein-Barr virus-immortalized b lymphoblasts carrying an activated C-MYC oncogene but not in Burkitt's lymphoma cell lines.
    Cariati R; Zancai P; Quaia M; Cutrona G; Giannini F; Rizzo S; Boiocchi M; Dolcetti R
    Int J Cancer; 2000 May; 86(3):375-84. PubMed ID: 10760826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The N-terminal domain of c-Myc associates with alpha-tubulin and microtubules in vivo and in vitro.
    Alexandrova N; Niklinski J; Bliskovsky V; Otterson GA; Blake M; Kaye FJ; Zajac-Kaye M
    Mol Cell Biol; 1995 Sep; 15(9):5188-95. PubMed ID: 7651436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-Myc overexpression promotes a germinal center-like program in Burkitt's lymphoma.
    Scheller H; Tobollik S; Kutzera A; Eder M; Unterlehberg J; Pfeil I; Jungnickel B
    Oncogene; 2010 Feb; 29(6):888-97. PubMed ID: 19881537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uncoupling of genomic instability and tumorigenesis in a mouse model of Burkitt's lymphoma expressing a conditional box II-deleted Myc protein.
    Fest T; Guffei A; Williams G; Silva S; Mai S
    Oncogene; 2005 Apr; 24(18):2944-53. PubMed ID: 15735723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant reduction of c-Myc expression and PI3K/AKT/mTOR signaling by quercetin induces a strong cytotoxic effect against Burkitt's lymphoma.
    Granato M; Rizzello C; Romeo MA; Yadav S; Santarelli R; D'Orazi G; Faggioni A; Cirone M
    Int J Biochem Cell Biol; 2016 Oct; 79():393-400. PubMed ID: 27620077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
    Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
    BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
    Arasi VE; Lieberman R; Sandlund J; Kiwanuka J; Novikovs L; Kirsch I; Hollis G; Magrath IT
    Cancer Res; 1989 Jun; 49(12):3235-41. PubMed ID: 2497974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of somatic mutation within translocated c-myc genes in Burkitt's lymphoma.
    Rabbitts TH; Forster A; Hamlyn P; Baer R
    Nature; 1984 Jun 14-20; 309(5969):592-7. PubMed ID: 6547209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanism of c-Myc and PRPS1/2 against thiopurine resistance in Burkitt's lymphoma.
    Li T; Song L; Zhang Y; Han Y; Zhan Z; Xv Z; Li Y; Tang Y; Yang Y; Wang S; Li S; Zheng L; Li Y; Gao Y
    J Cell Mol Med; 2020 Jun; 24(12):6704-6715. PubMed ID: 32391636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.